ClinicalTrials.gg

Spondylitis, Ankylosing clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 533 studies for Spondylitis, Ankylosing across more than 10 countries. 98 are recruiting or about to start. 361 of them are mainly about Spondylitis, Ankylosing (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 557 studies for Spondylitis, Ankylosing. How that becomes 531 here

This page counts the studies the registry files under Spondylitis, Ankylosing, and those it files under no condition that list Spondylitis, Ankylosingthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 557Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −6List Spondylitis, Ankylosing as a condition, but the registry did not file them under itMost often written as “Spondylarthropathies; Spondylitis, Ankylosing” (2), “Juvenile Ankylosing Spondylitis” (1), and “Active Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis” (1). The registry filed them under other conditions only, most often Spondylitis (3) and Spondylarthropathies (2).
  3. −20Match it another way17 name it in the title, 1 in a keyword, and 2 by a synonym or other text the search reads.
  4. 531The count on this page9 of them list Spondylitis, Ankylosing in their own words; the registry filed them under no condition.

Status

Completed
312
Status unknown
67
Recruiting
62
Not yet recruiting
33
Terminated
29
Active, not recruiting
13

Phase

Phase 3
85
Phase 2
60
Phase 4
59
Phase 1
20
Early Phase 1
4

Where

United States
87
Turkey
83
China
76
France
68
Germany
63
United Kingdom
42

Who develops what

Add Spondylitis, Ankylosing to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 8 programs from 8 companies, 7 with this as their studies’ main aim; 3 with a live phase 3 study; 3 primary completions in the next 12 months. Compare 3SBio, Beijing Gene Key Life Technology and Jiangsu vcare pharmaceutical technology here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
AdalimumabRecent, limited
Evidence
  • NCT06242652 · 3SBio Inc. · Phase 2 · live · comparator · “Adalimumab” · registered Jan 2024
  • NCT04135508 · Bio-Thera Solutions · Phase 3 · comparator · “Humira” · registered Oct 2019
  • NCT02893254 · Innovent Biologics, Inc. · Phase 3 · comparator · “Adalimumab” · registered Aug 2016
  • NCT02696785 · Eli Lilly and Company · Phase 3 · background · “Adalimumab” · registered Feb 2016
  • NCT01870284 · Eli Lilly and Company · Phase 3 · comparator · “Adalimumab” · registered Jun 2013
Abbott41% of its industry studiesUS: Amgen (FDA 2016) + 3 othersEU: AbbVie (EMA 2003) + 10 others11 study
tofacitinibRecent, limited
Evidence
  • NCT05814939 · Jiangsu vcare pharmaceutical technology co., LTD · Phase 2 · comparator · “Tofacitinib Citrate Tablets” · registered Apr 2023
Pfizer94% of its industry studiesUS: off-patent, 23 generics marketedEU: Pfizer (EMA 2017)11 study
DiclofenacEarlier only
Evidence
  • NCT00766402 · Johnson & Johnson · Phase 4 · comparator · “Diclofenac” · registered Oct 2008
  • NCT00762463 · Viatris Inc. · Phase 3 · comparator · “Diclofenac SR” · registered Sep 2008
  • NCT00648141 · Pfizer · Phase 3 · comparator · “Diclofenac” · registered Mar 2008
Novartis15% of its industry studiesUS: off-patent, 55 generics marketed00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
zemprocitinib☆ Track1 live phase-3 study: NCT07237568Lynk Pharmaceuticals Co., Ltd
608☆ Track1 live phase-3 study: NCT072616443SBio Inc.
VC005☆ Track1 live phase-3 study: NCT07172360Jiangsu vcare pharmaceutical technology co., LTD

The 3 in phase 3 with the nearest primary completion, of 8 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.zemprocitinib · Lynk Pharmaceuticals Co., Ltd · Phase 3 main aimNCT07237568 A Study to Evaluate Efficacy and Safety of LNK01001 in Adults With Ankylosing Spondylitis — primary endpoint: Percentage of Participants Achieving Assessment of SpondyloArthritis International Society 40 (ASAS40) Response at Week 16 · 352 enrolled
  • 14 Jan 2027 est.608 · 3SBio Inc. · Phase 3 main aimNCT07261644 A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS) — primary endpoint: The Percentage of Participants Who Achieved an Assessment of Spondylo Arthritis International Society (ASAS) 40 Response. · 500 enrolled
  • 30 Aug 2027 est.VC005 · Jiangsu vcare pharmaceutical technology co., LTD · Phase 3 main aimNCT07172360 Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis. — primary endpoint: Percentage of patients achieving an Assessment of disease activity (signs and symptoms) in ankylosing spondylitis 20% improvement (ASAS20) in response at week 12 of treatment. · 420 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Spondylitis, Ankylosing studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here JAK inhibitors 3 open · Tyrosine kinase inhibitors (TKIs) 3 open · NSAIDs 1 open · COX-2 inhibitors 1 open · Antimetabolites 1 open

Coming up

34studies finish main data collection within a year4 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 62 Spondylitis, Ankylosing studies recruiting now, 24 (39%) set no upper age limit and 32 (52%) stop at 75 or younger. 10 (16%) take children under 18. 0 (0%) are for women only and 1 (2%) for men only; 15 (24%) take healthy volunteers.

Recruiting studies that take each age, of 62
AgeWomenMen
107 (11%)7 (11%)
1856 (90%)57 (92%)
3061 (98%)62 (100%)
4061 (98%)62 (100%)
5059 (95%)60 (97%)
6552 (84%)53 (85%)
7534 (55%)34 (55%)
8529 (47%)29 (47%)

Across all 533 studies, recruiting or not: 42% stop at 75 or younger and 29% at 65; 9% take children; 1% are for women only and 1% for men only; 16% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Spondylitis, Ankylosing studies take

Of 40 phase 3 interventional studies under Spondylitis, Ankylosing, half reached primary completion within 21 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 215 mo12–31 · 22 studies——
Phase 321 mo15–32 · 40 studies21 mo15–28 · 38 studies—
Phase 432 mo25–36 · 18 studies——
Interventional, no phase12 mo7–20 · 64 studies—12 mo7–20 · 61 studies
Observational47 mo27–116 · 80 studies44 mo33–59 · 33 studies69 mo11–201 · 47 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 533. Browse all 533 → or search them.